New Stock News | Haina Pharmaceutical Plans to List in Hong Kong, China Securities Regulatory Commission Requires Supplemental Explanation of Specific Use of Funds Raised

According to the Zhitong Finance and Economics APP, on December 26th, the China Securities Regulatory Commission announced the "Supplementary Material Requirements for Overseas Issuance and Listing Registration (December 22, 2025 - December 26, 2025)". The International Department of the China Securities Regulatory Commission has published the supplementary material requirements for 19 companies, including the requirement for Haina Medicine to provide further explanation on the specific use of raised funds, the proportion of domestic and foreign use, and other issues. It is reported that Haina Medicine submitted its application to the Hong Kong Stock Exchange on November 7, 2025, with CICC as the sole sponsor.